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CARDIOLOGY

Pericardial Effusion with Tamponade Physiology
in a Patient with Multiple Myeloma
Sairamya Bodempudi MD, Rukaiya Bashir Hamidu MD, Preya Simlote MD, Shuwen Lin MD,
Philip Margiotta MD, Tina Boortalary MD, Gregary D. Marhefka MD

Figure 1. (A) RA diastolic collapse showing evidence of early tamponade.
(B) Plethoric IVC from a subcostal view. (C) Circumferential shot from a
subcostal view to show the extent of the pericardial effusion.

INTRODUCTION

CASE PRESENTATION

Both solid and hematological malignancies are known
to cause pericardial effusions. The hematological
malignancies that most often cause pericardial effusion
are leukemias, Non-Hodgkin’s lymphomas, and
Hodgkin’s lymphomas. 1 Patients can also develop
pericardial effusions from cancer-related causes, such
as chemotherapy, immunotherapy, radiation, or
infection.2 Although it has been reported in the literature
(approximately 27 cases between 1970 to 2019),
malignant pericardial effusion from multiple myeloma is
relatively uncommon.3,4 In addition, a rare but known
complication of poorly controlled multiple myeloma is
hyperviscosity syndrome, which typically presents as
spontaneous hemorrhage of the mucosal membranes,
headaches or neurological symptoms. We present a
case of a patient with multiple myeloma who was found
to have a pericardial effusion with tamponade that was
also complicated by hyperviscosity syndrome.

History of Present Illness
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A 78-year old African American female with a past
medical history of IgA Kappa Multiple Myeloma was
transferred to the Cardiovascular Intensive Care Unit
(CVICU) at Thomas Jefferson University Hospital (TJUH)
after being diagnosed with a pericardial effusion with
tamponade physiology at an outside hospital.
The patient was diagnosed with multiple myeloma 3
years prior on a left maxillary biopsy revealing a
plasmacytoma. Due to medical complications, multiple
hospitalizations, poor follow up, and intermittent refusal
of chemotherapy, the patient never achieved remission
of her malignancy. Due to continued progression of her
disease, she was started on Melphalan /methylprednisolone therapy and had finished 5 cycles.
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The patient was in her usual state of health until one
week prior to presentation when she developed a cough
and dyspnea on exertion. Since her symptoms
progressed, she eventually went to the emergency
department, where she was noted to have a pericardial
effusion with signs of early tamponade physiology. She
was transferred to the CVICU at TJUH for further care.
Upon arrival to TJUH, the patient was tachycardic with
heart rates in the 110s. A physical exam revealed
jugular venous distension, normal S1 and S2 heart
sounds, slight end expiratory wheezing throughout
the lung fields, and a droopy right eyelid with nodules.
A pulsus paradoxus was found to be 5 mm Hg and a
bedside transthoracic echocardiogram (TTE) showed
a circumferential pericardial effusion with a maximum
size of 2.2 cm, brief right atrial diastolic collapse, and
a non-compressible inferior vena cava concerning for
early tamponade physiology.

Hospital Course
Due to concern for tamponade, the patient received a
pericardiocentesis with pericardial drain placement.
Approximately 185 mL of sanguineous fluid was drained
and sent to the lab for typical studies, including cytology
plus flow cytometry. A repeat TTE showed trivial residual
pericardial effusion with improved hemodynamic profile
and resolution of tamponade. Pericardial fluid cytology
and flow cytometry results showed evidence of plasma
cells consistent with her underlying plasma cell myeloma.
Within a day of admission, the patient developed
significant interval swelling of her right eye with
ecchymosis of her medial upper eyelid and significant
conjunctival hemorrhage. Due to subjective shortness of
breath, a chest radiograph was done and showed the
correct positioning of the pericardial drain. However, it
incidentally showed new left sided pleural effusion. Given
multiple sites of spontaneous hemorrhage and
significantly elevated IgA levels (>4500), there was
concern for hyperviscosity syndrome. Medical oncology
was consulted and recommended urgent plasmapheresis,
however, the patient initially refused conveying her wishes
to pursue non-aggressive medical therapy. She was
temporized with intravenous fluids and high-dose steroids.
On day 7 of post-pericardial drain placement, there
continued to be high output (>75mL/day) from the
drain. Given the increased risk of infection with
prolonged drain placement and continued high output
in the setting of hyperviscosity syndrome, the decision
was made for doxycycline sclerotherapy to the
pericardium with subsequent removal of the pericardial
drain. Repeat TTE the following day showed only trivial
pericardial effusion.
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Eventually, the patient consented to plasmapheresis,
resulting in a downtrend of her IgA level. She received
cytoreductive chemotherapy with cyclophosphamide
and dexamethasone. The patient’s post-chemotherapy
hospital course was complicated by paroxysmal
supraventricular tachycardia, acute kidney injury, stressinduced hyperglycemia requiring insulin therapy and
febrile neutropenia from an unknown infectious source.
T h e s e co m p l i c at i o n s re s o l ve d w i t h m e d i c a l
management.
Prior to discharge, goals of care were readdressed.
Although initially hesitant, the patient and her family
ultimately decided to pursue aggressive treatment of
her multiple myeloma. She was subsequently
discharged to a sub-acute rehabilitation center after
which she under went chemotherapy with
daratumumab, pomalidomide, and dexamethasone.
Two months after the patient’s initial presentation to
the TJUH CVICU, the patient is doing well on her
current chemotherapy regimen with down trending IgA
levels. She has stable pleural effusions on chest x-ray.
Repeat TTE’s show no evidence of pericardial effusion.
She remains symptom free with no further medical
complications.

DISCUSSION & CONCLUSIONS
As stated previously, pericardial effusions secondary to
multiple myeloma are very rare, seen in < 1% of cases.4
Although in our case, the pericardial fluid was determined
to be malignant in origin based on flow cytometry and
cytology, the rapid re-accumulation of pericardial
effusion almost a week after drain placement was
presumed to be due to the spontaneous bleeding
complications of hyperviscosity syndrome. The medical
interventions were unique for this particular patient due
to her preference of treatments. She was initially
temporized with fluids and dexamethasone instead of
immediately being star ted on plasmapheresis.
Interestingly, temporizing measures did initially slow the
rate of drain output.
Despite stabilizing with steroids and fluids, the patient’s
re-accumulating pericardial effusion necessitated
management with sclerotherapy. Per review of literature,
doxycycline sclerotherapy for recurrent pericardial
effusions secondary to multiple myeloma has not been
performed.4 The decision to attempt bedside doxycycline
sclerotherapy highlights the role of shared-decision
making between the patient, her family, cardiology,
medical oncology, and thoracic surgery in order to
respect the patient’s wishes to opt for minimally invasive
treatment strategies.
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Our case also explores the complicated relationship
between management of plasma cell pericardial
effusions and hyperviscosity syndrome, which may
increase the risk of bleeding into the pericardium. When
the patient is clinically and hemodynamically stable, and
willing to receive plasmaphoresis, it is reasonable to treat
the hyperviscosity syndrome prior to draining the
pericardium to decrease the risk of post-intervention
bleeding. However, when a patient presents with early
signs of tamponade physiology or hemodynamic
instability, then a pericardiocentesis could be considered
and prioritized with simultaneous temporization of
hyperviscosity syndrome utilizing high-dose steroids and
fluids as we had done in this case. Finally, the case
demonstrates that it is essential to intermittently revisit
goals of care because our patient’s wishes evolved and
molded her medical management. On-going discussions
resulted in her changing her initial decision, and altering
the course of her disease process. Our case of a patient
with multiple myeloma presenting with malignant
pericardial effusion as an extra-medullary manifestation
of chemotherapy-refractory multiple myeloma is
therefore unique from a clinical presentation, medical
intervention, and a shared decision-making standpoint.
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